Synthesis of Tetrahydrobenzodiazepin-5-ones
2763
chloride (2 Â 25mL). The organic extract was washed with 5% sodium carbon-
ate solution, then water, and dried (MgSO4). The solvent was removed and the
residue was purified by column chromatography using methylene chloride-ethyl
acetate (20 : 1) to give compound 3c (0.52 g, 87%) as an oil. Anal. calcd for
C12H13NO3(219.24): C, 65.74; H, 5.98; N, 6.39. Found: C, 65.81; H, 6.16; N,
1
6.30. IR (KBr): 1675, 1645cm21; H-NMR (CDCl3): 2.13 (s, 3H, CH3), 2.75
(2H, m, 3-H), 3.4 (1H, m, 2-H), 3.87 (3H, s, OCH3), 5.0 (1H, m, 2-H), 7.12
(1H, dd, J ¼ 8.2 and 1.4 Hz, 7-H), 7.22 (1H, t, J ¼ 8.2 Hz, 6-H), 7.56 (1H,
dd, J ¼ 8.2 and 1.4 Hz, 5-H); 13C-NMR (CDCl3): 21.9, 40.1, 44.1, 55.9,
117.2, 119.3, 127.0, 128.5, 134.1, 152.4, 171.1, and 194.9.
Schmidt Expansion on 1,2,3,4-Tetrahydroquinolin-4-ones. General
Procedure. Concentrated sulfuric acid (2.5 mL) was added slowly to a
stirred solution of quinolone 3 (500 mg) in chloroform (5 mL) at 08C, then
sodium azide (500 mg) was added gradually over 30 min. After 3 hr at room
temperature, the reaction mixture was cooled and then neutralized with 10%
aqueous solution of NaHCO3 and extracted with ethyl acetate. The extract
was dried with NaSO4 and filtered. The filtrate was chromatographed on a
silica gel column with ethyl acetate/methylene chloride.
6-Methoxy-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-one (4a) and
9-methoxy-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-5-one (5a). From qui-
nolone 3a obtained in order of elution, 4a (18%), RF 0.50 (ethyl acetate),
m.p. 140–1418C. Anal. calcd for C10H12N2O2 (192.22): C, 62.49; H, 6.29;
N, 14.57. Found: C, 62.20; H, 6,10; N, 14.50. IR (KBr): 3365, 3310, 3170,
1
1669 cm21; H-NMR (CDCl3): 2.77 (2H, t, J ¼ 5.7 Hz, 3-CH2), 3.62 (2H, t,
J ¼ 5.7 Hz, 4-CH2), 3.85 (3H, s, OCH3), 4.4 (1H, br s, NH), 6.53 (1 H, dd,
J ¼ 8.0 and 1.5 Hz, 7-H), 6.57 (1H, dd, J ¼ 8.0 and 1.5 Hz, 9-H), 6.71 (1H,
t, J ¼ 8.0 Hz, 8-H), and 8.16 (1H, br s, HNC55O); 13C-NMR (CDCl3): 37.1,
45.0, 55.9, 106.0, 114.5, 118.5, 125.2, 128.9, 149.3, and 174.0; and 5a
(70%), RF 0.23 (ethyl acetate), m.p. 201–2028C. Anal. calcd for
C10H12N2O2 (192.22): C, 62.49; H, 6.29; N, 14.57. Found: C, 62.30; H,
1
6,15; N, 14.45; IR (KBr): 3195, 1655 cm21; H-NMR (CDCl3): 3.55 (4H,
m, 2-CH2 and 3-CH2), 3.83 (3H, s, OCH3), 4.3 (1H, br s, NH), 6.66 (1H, t,
J ¼ 8.0 Hz, 7-H), 6.82 (1H, dd, J ¼ 8.0 and 1.2 Hz, 8-H), 7.42 (1H, br s,
HNC55O), and 7.61 (1H, dd, J ¼ 8.0 and 1.2 Hz, 6-H); 13C-NMR (CDCl3):
42.3, 48.3, 56.0, 111.6, 115.8, 116.6, 124.7, 136.8, 147.3, and 172.0.
6-Hydroxy-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-one (4b) and
9-Hydroxy-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-5-one (5b). From qui-
nolone 3a obtained in order of elution, 4b (22%), RF 0.30 (ethyl acetate),
m.p. 219–2208C. Anal. calcd for C9H10N2O2(178.19): C, 60.67; H, 5.66; N,
15.72. Found: C, 60.40; H, 5.35; N, 15.50. IR (KBr): 3376, 3177,
;
1646 cm21 1H-NMR (DMSO-d6): 2.55 (2H, m, 3-CH2), 3.53 (2H, m,
4-CH2), 4.94 (1H, br s, NH), 6.6 (3H, m, ArH), 9.38 (1H, s, OH) and 9.63